PR NewswireJuly 12, 2019 DENVER, July 12, 2019 /PRNewswire/ — Ur-Energy Inc. (NYSE American: URG; TSX: URE) (“Ur-Energy”) and Energy Fuels Inc. (NYSE American: UUUU; TSX: EFR) (“Energy Fuels”) confirm that they are unaware of any decision by the White House with respect to the U.S. Department of Commerce (“DOC”) investigation into the effects of uranium…
DetailsGlobeNewswire•June 19, 2019 OXNARD, Calif. , June 19, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it is collaborating with Canopy Growth Corporation (WEED.TO) (CGC), (“Canopy”) to develop a new low-dose cannabidiol (CBD) oral thin film (OTF) using CURE’s patented CUREfilm™ technology for global distribution. This CUREfilm…
DetailsGlobeNewswire•June 3, 2019 VANCOUVER, British Columbia, June 03, 2019 (GLOBE NEWSWIRE) — Wealth Minerals Ltd. (the “Company” or “Wealth”) – (TSXV: WML; OTCQX: WMLLF; SSE: WMLCL; Frankfurt: EJZN) announces that, further to its news releases dated December 4, 2018 and April 4, 2019, its wholly-owned subsidiary, Wealth Copper Ltd. (“Wealth Copper”) has entered into a…
DetailsGlobeNewswire•May 30, 2019 LOS ANGELES, May 30, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced that it will be presenting at the 9th Annual LD Micro Invitational on Wednesday, June 5th at 11:40 a.m. PT at the Luxe Sunset Boulevard Hotel in Los Angeles. The conference will…
DetailsGlobeNewswire•May 22, 2019 OXNARD, Calif., May 22, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced the issuance of U.S. Patent No. 10,307,397, which covers the high load of bioactive cannabinoid molecules integrated into oral thin film dosage forms. The cannabinoids include cannabidiol (CBD) and tetrahydrocannabinol (THC). “Advances…
DetailsGlobeNewswire•May 20, 2019 OXNARD, Calif., May 20, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical(CURR), an innovative drug delivery and development company, today announced the addition of four key hires to their growing leadership team. Michael Redard will serve as CURE’s Chief Financial Officer. Josh Held becomes an independent new board member, Bhaumik Patel is CURE’s director…
DetailsGlobeNewswire•May 14, 2019 Acquired Technology Expands Core CUREfilmTM Platform and Strengthens Balance Sheet OXNARD, Calif., May 14, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical(CURR) (“CURE”), an innovative drug delivery and development company, today announced that it has closed on the previously announced acquisition of Chemistry Holdings Inc. (“Chemistry Holdings”, “CH”), a formulation technology company that is…
DetailsGlobeNewswire•May 2, 2019 CHICAGO, May 02, 2019 (GLOBE NEWSWIRE) — Today, at the CPhI Conference, Meroven LLC announced a five-year agreement with CURE Pharmaceutical Corporation (CURR) to exclusively market and distribute Spee-D®, a weekly dose oral thin film Vitamin D3 in the USA. Under the terms of the agreement, Meroven LLC will be responsible for…
Details